It Begins with a Vacation
The story of ChinaBio® starts with a vacation... In November 2006, our founder, Greg Scott, visited China for the first time. He had arranged to have one business meeting while he was in Shanghai at Zhangjiang Hi-Tech Park. From that single meeting, and a brief tour of the 25 sq. km Park where he saw Roche, Pfizer, GSK, Lilly, and over 200 early-stage biotech companies, he knew he would be coming back to China. His 10-years of experience as an angel investor in biotech in the US led him to believe that there was something "big" happening in China, and he had to find out more.
So in late January 2007, he returned for one week with only two scheduled meetings. By the end of the week and over 30 meetings, the seeds of ChinaBio® were sown. By April, ChinaBio's offices were open in the Biotech VC Plaza building in Zhangjiang Hi-Tech Park, and the first staff was hired. While often told he was one of the very few interested in early-stage biotech/medtech in China, his interest remained high as he worked with several promising companies.
The World Discovers China Biotech
Then, in August 2007, WuXi PharmaTech went public, quickly followed by several other China biotech IPOs. Suddenly the world knew there was a biotech industry in China and wanted to know more and began beating a path to ChinaBio's door. Our staff of two has quickly grown to nearly 20, including four PhDs, two MBAs, several masters, and a JD/LLB. ChinaBio's latest additions are the opening of our fourth office in Basel Switzerland, and the creation of BioPacific Investors, a private equity investment group focused on bringing western products and technologies to China.
ChinaBio's consulting group, launched in 2008, has now helped some of the world's most prestigious life science companies achieve success in China, including Pfizer, Roche, Roche Diagnostics, Bayer, Merck, Shire, and Thermo Fisher/Life Technologies, among others. Our research team tracks China's life science industry including novel technology development, government funding, clinical trial activity, VC investments, IPOs and M&A and partnering activity, and publishes three white papers each year. This information gives our clients critical insights into the direction of the industry and how China will impact the future of the global biopharma industry.
At the end of 2007, ChinaBio held its first conference, the ChinaBio® Investor Forum, which attracted over 150 attendees and 15 presenting companies. ChinaBio has now organized over 30 major conferences in China, including its well respected ChinaBio® Partnering Forum which attracts over 1000 attendees each spring, as well as the invitation-only ChinaBio® Leadership Retreat and our ChinaBio® Investor Forums. (See Upcoming Events.)